Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX464 Long-term Extension in Ulcerative Colitis
NCT03368118Phase 2Completed
- Sponsor
- Abivax
- Start
- Jan 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of obefazimod in ulcerative colitis (UC), sponsored by Abivax. Started Jan 2018; status: completed.
02
Drugs
obefazimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03368118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03368118.